Dersimelagon (MT-7117)

Name: Dersimelagon (MT-7117) in Erythropoietic protoporphyria or X-linked protoporphyria: Average sales price and wholesale acquisition cost
Published: 2026-09-21T21:42:40-04:00

Erythropoietic protoporphyria or X-linked protoporphyria

Manufacturer: LEO Pharma
Regulatory submission: NDA submitted June 2026
Launch: Potential launch in 2027
Last updated: September 21, 2026

Section

Product information and disease description Product description Product information

Average sales price and wholesale acquisition cost

1 evidence topic · 1 source

United States wholesale acquisition cost and average sales price

No evidence found.

Expected annual cost per patient in the Dutch horizon scan

“Cost” (opens the source at this quote in a new tab)
“€ 71,000.00” (opens the source at this quote in a new tab)
“This amount gives an indication of the total cost. It is the result of the average expected patient volume times the average cost per patient. both per year” (opens the source at this quote in a new tab)